Skip to content

KZIA

Kazia Therapeutics Ltd.

NASDAQ · Healthcare · Biotechnology · AU

$10.39
−4.33%
Ask drillr

Year over year

Reported trailing growth

Revenue
-99.2%
EBITDA
+33.0%
EBIT
+37.3%
EPS
+72.3%
Free cash flow
-21.7%
Operating cash flow
-77.3%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+61.3%
EBITDA
+50.1%
EBIT
+50.0%
Net income
+22.7%
EPS
+65.6%
Free cash flow
-38.6%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025